.jpeg)
2026-10-08 07:21:15
Zenocutuzumab is an intravenous HER2×HER3 bispecific antibody for adults with confirmed NRG1 gene fusion across selected advanced solid tumors. FDA covers NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma after prior systemic progression; standard 750mg IV every 2 weeks. eNRGy supports ORR and duration, with monitoring for infusion reactions, diarrhea, left ventricular function, and embryo-fetal risk.
2026-09-30 02:53:55
Juvmo is a selective dopamine D1/D5 partial agonist for adult Parkinson’s motor symptoms. It can be used as early monotherapy or with levodopa for motor fluctuations, 5–15mg once daily. TEMPO trials improved MDS‑UPDRS and extended on‑time without troublesome dyskinesia; monitor orthostatic hypotension, somnolence, hallucinations, impulse control, and dyskinesia.
2026-09-30 02:43:37
Emcitate contains tiratricol (TRIAC), an oral thyroid hormone analog for peripheral thyrotoxicosis in all ages with MCT8 deficiency (Allan‑Herndon‑Dudley syndrome). It acts without relying on MCT8, reduces serum T3, and improves tachycardia, catabolism, and weight issues; it does not reverse established neurodevelopmental impairment and requires weight‑based, thyroid‑function‑guided monitoring of heart rate and bone metabolism.
2026-09-29 07:19:23
Lyrfigtu is an oral selective FGFR2 kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma and FGFR2 fusion/rearrangement. In REFOCUS, 70mg once daily gave independent-review ORR about 46% and median DOR 11.8 months; monitor retinal disease, hyperphosphatemia, soft-tissue mineralization, and embryo-fetal risk.
2026-09-29 06:25:46
Pemigatinib is an oral FGFR1/2/3 inhibitor for advanced FGFR2 fusion/rearrangement cholangiocarcinoma and selected FGFR1-rearranged myeloid/lymphoid neoplasms. Cholangiocarcinoma uses 13.5mg once daily, 14 days on and 7 days off; FIGHT-302 and FIGHT-202 support sequencing decisions, with serum phosphate and OCT ophthalmology monitoring.
2026-09-28 04:52:25
Belumosudil is a ROCK2 inhibitor for chronic graft-versus-host disease in patients aged 12 years and older after inadequate response to prior systemic therapy. Use 200mg once daily with food; manage embryo-fetal risk and contraception, strong CYP3A inducers/PPI dosing changes, monthly liver tests, and infection or hypertension adverse events.
2026-09-28 04:44:36
Elagolix is an oral GnRH receptor antagonist that lowers LH/FSH and ovarian estrogen for moderate-to-severe endometriosis pain, including dysmenorrhea, non-menstrual pelvic pain, and dyspareunia. It is not a conventional analgesic and not an oncology targeted drug; use 150mg once daily or 200mg twice daily with bone-density, mood, liver, and pregnancy monitoring.
2026-09-28 04:39:37
Diazoxide oral suspension opens β-cell KATP channels and suppresses insulin release for hyperinsulinemic hypoglycemia. Adults/children start 3mg/kg/day up to 8mg/kg/day, infants/newborns 8–15mg/kg/day; inadequate response means re-check cause rather than simply increasing dose, with monitoring for fluid retention, hyperglycemia, hypotension, and neonatal pulmonary hypertension.
2026-09-28 04:24:07
Ambrisentan is a selective endothelin-A receptor antagonist studied as adjunctive therapy for persistent IgA-nephropathy proteinuria despite baseline treatment. Real-world data show urine protein reduction and some hematuria improvement, but hemoglobin drop, edema, hypotension, liver tests, and renal function need monitoring.
2026-09-28 04:14:55
Dabrafenib (Tafinlar) is an oral BRAF inhibitor active only in tumors with a BRAF V600E/K mutation. This guide covers its mechanism, FDA-approved indications, adult and pediatric dosing, the evidence for combining it with trametinib, and practical management of adverse reactions.
2026-09-22 08:14:01
How binimetinib adds MEK1/2 blockade to encorafenib in BRAF V600E/K unresectable or metastatic melanoma, covering mechanism, response, resistance and monitoring.
2026-09-20 04:37:17
Lemborexant is a dual orexin receptor antagonist for adults with sleep-onset or sleep-maintenance insomnia. Start 5mg at bedtime with at least 7 hours in bed, titrate to 10mg by response; assess sleep latency, night awakenings, return-to-sleep, and next-day function, and watch daytime sedation, sleep paralysis, hallucinations, and complex sleep behaviors.
